Abivax reports ulcerative colitis trial cancer rates align with expectations
read at Endpoints ↗Positive readoutPositive
Abivax released new data from its Phase 3 trial of an ulcerative colitis candidate.
The data show that the number of cancer cases observed was within the range normally expected for ulcerative colitis patients, addressing prior safety concerns.
The company said the findings support continued development of the drug and reduce worries about oncogenic risk.
No new efficacy data were disclosed, and the trial remains ongoing.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Abivax aims to set cancer concerns with ulcerative colitis drug to rest”
read at Endpoints ↗91 words · retrieved Jul 1
comments(0)
5-min edit window · permanent after that